Sign in
Not yet taking people in NetherlandsPhase 4

Long-term follow-up of enzyme therapy in people with Pompe disease

Follows children and adults with Pompe disease receiving enzyme replacement therapy over time.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Rotterdam, NetherlandsSee the site
Registry title
Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease
Status
Not yet recruiting
Phase
Phase 4
People taking part
156 people, planned
Started
22 Jun 2007
Planned end
22 Jun 2025
Type of study
Interventional
Record updated
16 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults with confirmed Pompe disease who have symptoms and are approved to start enzyme therapy.

Age
No age limit. Children under 12 have a different blood-drawing plan.
Sex
All sexes can join.
Disease stage
Must have symptoms of Pompe disease: weak skeletal muscles, lower lung function (FVC below 80% sitting), or a thickened heart muscle.
Earlier treatment
Start of enzyme therapy must have been approved by the "indicatie commissie".
Biomarker or test result
Pompe disease confirmed by low α-glucosidase activity in white blood cells, skin cells or muscle, or by a known α-glucosidase gene mutation. A skin biopsy is needed to measure the remaining activity.

Main reasons for not taking part

  • People who are not likely to benefit from treatment

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients should have a proven diagnosis of Pompe disease, which means that the diagnosis is confirmed by deficiency of α-glucosidase activity in leukocytes, fibroblasts or skeletal muscle, or by a documented mutation in the α-glucosidase gene. A skin biopsy is required to assess the level of residual α-glucosidase activity
  • There is no age limit for participation in the study, but the protocol for children < 12 years of age differs in the amount of blood that will be drawn (appendix 1)
  • Patients have had at least one evaluation through which the severity of the disease has been assessed and the urgency of enzyme therapy can be determined. During this evaluation at least pulmonary function and muscle strength and function will be assessed
  • The order in which adult patients with Pompe disease will be enrolled is determined by the “indicatiecommissie” (appendix 2). For patients who show rapid progression of disease or for children the need for enzyme therapy will be discussed on a case by case basis
  • The patient must have symptoms of Pompe disease being:  Signs of skeletal muscle weakness, or  Decreased pulmonary function (FVC < 80% in sitting position), or  Cardiac hypertrophy
  • Start of treatment has been approved by the “indicatie commissie”
  • Written informed consent must be obtained from the patient and/or from the patient's parent/guardian if the patient is under 18 years of age (see section 6.1)

Who cannot take part

  • Cases who are not likely to benefit from treatment

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

• Increase knowledge on the long term clinical effects of enzyme replacement therapy and to improve the level of care in children and adults with Pompe disease • Obtain data to support continuation of reimbursement by the Dutch health authorities after the initial 3 years • Assess the economic burden of Pompe disease (inventory of the costs of (medical) care, informal care and loss of productivity) and effects of enzyme therapy on these costs • Improve the efficacy (“doelmatigheid”) of enzyme therapy: • Development of guidelines when to start or stop enzyme therapy; • Should dosing be advised per kg body weight or per kg lean body mass • Safely install enzyme therapy at home • Learn more about atrophy and regeneration capacity of skeletal muscle in children and adults

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease; Long-term follow-up of patients receiving commercially available Myozyme
Plain-language title
Long-term follow-up of enzyme therapy in people with Pompe diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 December 2024